

# PRESS



## **EPIDAUROS enters into Sales & Marketing agreement with InPheno**

November 30, 2006

**Bernried, Germany / Basel, Switzerland** - November 30, 2006 - EPIDAUROS Biotechnologie AG, a leading pharmacogenetic research organization located in Bernried near Munich, and InPheno AG, a Basel (Swiss)-based provider of novel diagnostic methodologies in the areas of virology and oncology, jointly announce today that both companies entered into a mutually beneficial Sales & Marketing partnership. Financial details are not disclosed.

Both partners intend to generate new business opportunities by jointly applying their unique skills and capabilities in the areas of genotyping and phenotyping with a particular focus on specific disease areas, such as virology and oncology.

Thomas Klimkait, Chief Executive Officer at InPheno, commented: "We are delighted to jointly explore business opportunities with one of the leading providers of pharmacogenetic solutions at the growing interface of genotyping and phenotyping in the near future. EPIDAUROS with its strong customer base in the pharma industry is an excellent partner in this regard." "The addition of InPheno's medical-based capabilities in important diseases, such as virology and oncology, clearly open up an important expansion to our well established service offering around high-quality clinical genotyping", Michael Lutz, Chief Executive Officer at EPIDAUROS added.

### **Contacts:**

#### **EPIDAUROS Biotechnologie AG**

Michael Lutz, Ph.D.  
Chief Executive Officer  
Am Neuland 1, D-82347 Bernried  
Phone: +49 (0)8158 9985 0  
Fax: +49 (0)8158 9985 48  
Email: [contact@epidauros.com](mailto:contact@epidauros.com)

#### **InPheno AG**

Thomas Klimkait, PD Ph.D.  
Chief Executive Officer  
Vesalgasse 1, CH-4051 Basel  
Phone: +41 (0)61 267 3542  
Fax: +41 (0)61 267 3538  
Email: [info@inpheno.com](mailto:info@inpheno.com)

# PRESS



## **About EPIDAUROS Biotechnologie AG**

([www.epidauros.com](http://www.epidauros.com))

EPIDAUROS Biotechnologie AG is a leading provider of tailor-made pharmacogenetic solutions in the area of clinical drug development. The company investigates the individual genetic profile that influences a person's response to a drug in order to make drug development and therapy safer and more efficient. EPIDAUROS examines and characterizes variations (polymorphisms) of genes that encode for drug transporter proteins, drug metabolizing enzymes and drug targets, e.g. receptors.

EPIDAUROS' business activities range from scientific pharmacogenetic consultancy, conduct of logistics for sample collection and shipment, sample processing and genetic testing in its own laboratory, up to data analysis and submission-ready reporting. In addition, provision of services includes development of new assays for genetic testing and extensive analysis of pharmacogenetic data, e.g. with regard to haplotypes (linked genetic markers).

EPIDAUROS explores new polymorphisms with pharmacogenetic relevance in close collaboration with leading academic institutions. In addition, the company also offers a concept for the development of drugs with companion diagnostics to the pharmaceutical industry. Moreover, EPIDAUROS develops genetic tests for routine use together with diagnostics companies.

## **About InPheno AG**

([www.inpheno.com](http://www.inpheno.com))

InPheno AG, based in Basel, Switzerland, is a leading provider of functional pharmacophenomic services with focus on the application of proprietary phenotyping technologies in lead finding, resistance monitoring and drug treatment optimization in the fields of viral diseases, especially HIV, hepatitis and cancer diseases. InPheno's core competencies lie in assay development, lead finding and profiling of molecularly targeting modalities and in applications for clinical resistance monitoring for established and novel drugs.

InPheno AG provides its services preferably as long-term partner in R&D collaborations but also in single project agreements with pharma and biotechnology companies. The diagnostic services for the treating physician include insurance-reimbursed geno- and phenotypic resistance-assessment for HIV towards minimizing clinical resistance development and optimizing long-term therapy. InPheno AG has close links to the accredited Diagnostics Institute of Medical Microbiology, Basel, Switzerland with collaboration agreements for the provision of logistics support as well as scientific and technological input for future developments.

InPheno's services are offered worldwide.